Feasibility and safety of autologous bone marrow mononuclear cell transplantation in patients with advanced chronic liver disease

Table 3 Characteristics of the distribution of laboratory parameters in 10 patients with chronic liver failure at baseline, 1 and 4 mo after BMC transplantation

	Minimum	Maximum	Mean	Median	Standarddeviation	Relative meanchange frombaseline (%)
Hemoglobin (g/dL)
Baseline	11.30	16.90	13.16	12.2	1.90
1 mo	9.50	16.00	12.26	11.95	1.81	-8
4 m	10.30	15.10	12.80	12.7	1.47	-3
WBC (x 103/mm3)
Baseline	2.60	5.40	3.94	4	0.97
1 mo	2.30	5.10	3.35	2.85	1.04	-15
4 mo	2.30	6.00	3.60	3.25	1.14	-9
GGT (U/L)
Baseline	50.00	543.00	172.20	139	147.50
1 mo	48.00	474.20	157.20	134.5	129.00	-9
4 mo	47.00	489.67	163.50	132.5	133.25	-5
AST (U/L)
Baseline	29.00	192.00	100.60	92.5	56.24
1 mo	26.00	173.00	86.90	79	47.58	-14
4 mo	29.00	180.00	85.80	64	46.87	-15
ALT(U/L)
Baseline	11.00	120.00	56.00	43	35.54
1 mo	22.00	115.00	54.80	42.5	32.71	-2
4 mo	17.00	131.00	53.50	41	34.97	-4
Creatinine (mg/dL)
Baseline	0.60	1.50	0.86	0.8	0.26
1 mo	0.70	1.30	0.90	0.85	0.20	5
4 mo	0.60	1.20	0.87	0.85	0.19	1